Imagine a World Where metabolic balance is the norm,And patients live without compromise. " We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two ongoing Phase 3 trials in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update 11/06/25 Rezolute to Host Virtual Investor Event on Ersodetug Development Program 11/05/25 Rezolute to Participate in Upcoming Investor Conferences 10/15/25
